PMID- 30428868
OWN - NLM
STAT- MEDLINE
DCOM- 20190129
LR  - 20221207
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 17
IP  - 1
DP  - 2018 Nov 14
TI  - Changes in peroxisome proliferator-activated receptor alpha target gene 
      expression in peripheral blood mononuclear cells associated with non-alcoholic 
      fatty liver disease.
PG  - 256
LID - 10.1186/s12944-018-0901-7 [doi]
LID - 256
AB  - OBJECTIVE: To identify differences in the expression of peroxisome 
      proliferator-activated receptor alpha (PPARalpha) target genes in human peripheral 
      blood mononuclear cells (PBMCs) associated with non-alcoholic fatty liver disease 
      (NAFLD) among Chinese individuals. METHODS: Thirty healthy subjects were selected 
      as the control group (CN), and 43 patients newly diagnosed with NAFLD were 
      subdivided into two groups, non-obese group (NF, n = 21) and obese group (OF, 
      n = 22). Expression of PPARalpha and its target genes was determined in PBMCs. The 
      levels of liver cell damage markers, total cholesterol (TC), triglyceride (TG), 
      free fatty acids (FFA), glucose, and insulin were determined in serum. RESULTS: 
      Compared to the CN group, the blood pressure and homeostasis model assessment for 
      insulin resistance (HOMA-IR) were increased in the other groups (P < 0.05), while 
      the systolic blood pressure (SBP) and liver cell damage markers were 
      significantly increased in the OF group (P < 0.05). In the OF group, PPARalpha target 
      gene expression was 2.03-3.31 times higher than that in the CN group, and a 
      negative correlation was found between PPARalpha target gene expression and abdominal 
      circumference (AC), body mass index (BMI), diastolic blood pressure (DBP). 
      Additionally, solute carrier family 25 (carnitine/acylcarnitine translocase) 
      member 20 (SLC25A20) and acyl-coenzyme A dehydrogenase 2 long chain (ACADVL) were 
      negatively correlated with HOMA-IR; PPARalpha, acetyl-coenzyme A dehydrogenase 2 
      (ACAA2), and carnitine palmitoyltransferase 1A (CPT1A) were positively correlated 
      with HOMA-IR. CONCLUSION: There is an up-expression of PPARalpha target genes in the 
      PBMCs of NAFLD patients, possibly leading to changes in beta-oxidation and insulin 
      resistance.
FAU - Li, Tian Tian
AU  - Li TT
AD  - Medical Experimental Center of Qilu Hospital (Qingdao), Shandong University, 
      Qingdao, 266035, China.
FAU - Tan, Tian Bi
AU  - Tan TB
AD  - Dynacare, 150 Montreal Road, Ottawa, ON, Canada.
FAU - Hou, Hai Qing
AU  - Hou HQ
AD  - Clinical Lab of Qilu Hospital (Qingdao), Shandong University, Qingdao, 266035, 
      China.
FAU - Zhao, Xiao Yun
AU  - Zhao XY
AD  - Clinical Lab of Qilu Hospital (Qingdao), Shandong University, Qingdao, 266035, 
      China. 18561810828@126.com.
AD  - Qingdao Key Lab of Mitochondrial medicine, Hefei Road No 758, Qingdao, 266035, 
      China. 18561810828@126.com.
LA  - eng
GR  - 2014WS0130/Shandong Medical and Health Science and Techology Development Plan/
PT  - Journal Article
DEP - 20181114
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (PPAR alpha)
SB  - IM
MH  - Adult
MH  - Asian People
MH  - *Gene Expression Regulation
MH  - Humans
MH  - Insulin Resistance
MH  - Leukocytes, Mononuclear/*metabolism
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/*metabolism
MH  - PPAR alpha/*genetics
PMC - PMC6236948
OTO - NOTNLM
OT  - Insulin resistance
OT  - NAFLD
OT  - Obesity
OT  - PBMC
OT  - PPARalpha
COIS- ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Permission of this study was granted 
      by the Ethics Committee of Human Research at the Medical Examination Center, 
      Shandong University Qilu Hospital, China (KYLL-2017031). CONSENT FOR PUBLICATION: 
      All subjects gave their written informed consent to participate in this study. 
      COMPETING INTEREST: The authors declare that they have no competing interests. 
      PUBLISHER'S NOTE: Springer Nature remains neutral with regard to jurisdictional 
      claims in published maps and institutional affiliations.
EDAT- 2018/11/16 06:00
MHDA- 2019/01/30 06:00
PMCR- 2018/11/14
CRDT- 2018/11/16 06:00
PHST- 2018/06/19 00:00 [received]
PHST- 2018/10/24 00:00 [accepted]
PHST- 2018/11/16 06:00 [entrez]
PHST- 2018/11/16 06:00 [pubmed]
PHST- 2019/01/30 06:00 [medline]
PHST- 2018/11/14 00:00 [pmc-release]
AID - 10.1186/s12944-018-0901-7 [pii]
AID - 901 [pii]
AID - 10.1186/s12944-018-0901-7 [doi]
PST - epublish
SO  - Lipids Health Dis. 2018 Nov 14;17(1):256. doi: 10.1186/s12944-018-0901-7.